Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H1 2016

Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H1 2016
Published Jun 30, 2016
49 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H1 2016, provides in depth analysis on Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A)
- The report reviews Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A)<

  
Source:
Document ID
GMDHC0172TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) Overview61
Therapeutics Development73
  Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) Products under Development by Stage of Development71
  Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) Products under Development by Therapy Area81
  Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) Products under Development by Indication91
Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) Pipeline Products Glance102
  Late Stage Products101
  Early Stage Products111
Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) Products under Development by Companies122
Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) Therapeutics Assessment146
  Assessment by Monotherapy/Combination Products141
  Assessment by Mechanism of Action151
  Assessment by Route of Administration162
  Assessment by Molecule Type182
Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) Companies Involved in Therapeutics Development203
  AbbVie Inc.201
  Handok Inc.211
  XBiotech USA, Inc.221
Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) Drug Profiles2313
  ABT-981 Drug Profile231
  CV-18C3 Drug Profile242
  HL-2351 Drug Profile261
  Monoclonal Antibodies to Inhibit IL-1a for Myocardial Infarction and Atherosclerosis Drug Profile271
  RA-18C3 Drug Profile282
  T2-18C3 Drug Profile301
  Xilonix Drug Profile315
Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) Dormant Projects361
Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) Featured News &Press Releases3711
  Jun 08, 2016: Appoints Trey Benson as New Commercial Head to Lead Strategic Commercial Development for the Companys Extensive Product Portfolio371
  May 24, 2016: XBiotech to Present Positive Preliminary Survival Data on Xilonix(TM) at the 18th European Society of Medical Oncology World Congress on Gastrointestinal Cancer371
  Apr 19, 2016: XBiotech to Present Pivotal Phase 3 Data on Xilonix at European Society of Medical Oncology s World Congress on Gastrointestinal Cancer381
  Apr 04, 2016: European Medicines Agency Grants Accelerated Assessment of Marketing Authorization Application for Xilonix, XBiotech s True Human Therapeutic Antibody Treatment for Advanced Colorectal Cancer391
  Mar 23, 2016: XBiotech Announces European Medicines Agency Validates Marketing Authorization Application for Xilonix in the Treatment of Advanced Colorectal Cancer391
  Mar 08, 2016: XBiotech Announces Submission of Marketing Authorization Application for Candidate Colorectal Cancer Therapy to European Medicines Agency401
  Mar 04, 2016: European Medicines Agency Grants Eligibility for Submission of XBiotech s Marketing Authorization Application411
  Mar 02, 2016: XBiotech to Deliver Presentation on Novel Study Design and Phase III Results From European Study on Xilonix During Meeting at the European Parliament421
  Jan 21, 2016: XBiotech to Attend and Present at the ASCO 2016 Gastrointestinal Cancers Symposium421
  Jan 08, 2016: XBiotech Reports Additional Positive Data From Phase III European Trial of Xilonix in Advanced Colorectal Cancer431
  Dec 07, 2015: XBiotech Announces Positive Results in European Phase III Study for Its Breakthrough Therapy for Colorectal Cancer441
  Nov 23, 2015: XBiotech Provides Update on Phase III Oncology Study in Europe451
  Nov 03, 2015: AbbVie to present abstract on ABT-981 at the American College of Rheumatology Annual Meeting461
  Oct 02, 2015: XBiotech Announces Publication of Clinical Results Supporting the Potential of Its True Human Antibody as a Cardiovascular Therapy461
  Aug 17, 2015: XBiotech Completes Enrollment for Xilonix Phase III Registration Study in Europe471
Appendix482
  Methodology481
  Coverage481
  Secondary Research481
  Primary Research481
  Expert Panel Validation481
  Contact Us481
  Disclaimer491

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Interleukin-1-Alpha-IL-1-Alpha-or-Hematopoietin-1-or-IL1A-Pipeline-Review-H1-2016-2088-16082>
  
APA:
Global Markets Direct - Market Research. (2016). Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Interleukin-1-Alpha-IL-1-Alpha-or-Hematopoietin-1-or-IL1A-Pipeline-Review-H1-2016-2088-16082>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.